The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher ...
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...